Drug Trial Radar · NCT01360645
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Last checked: Nov 20, 2026Latest source record: Nov 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
826
Actual
Start
Jul 2011
Primary completion
May 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
Conditions
- Depressive Disorder
- Depression
- Depressive Disorder, Major
- Mood Disorders
- Mental Disorders
Interventions
OPC-34712 + ADTDrug
Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + ADTDrug
Placebo + FDA Approved Antidepressant (ADT)
Placebo + ADTDrug
Placebo + FDA Approved Antidepressant (ADT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample.Time frame: Baseline and Week 14
- Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol.Time frame: Baseline and Week 14
Locations
57 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Arcadia, California
Research Site
Beverly Hills, California
Research Site
Fresno, California
Research Site
Oceanside, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
Sherman Oaks, California
Research Site
Denver, Colorado
Research Site
Norwalk, Connecticut
Research Site
Coral Springs, Florida
Research Site
Fort Myers, Florida
Research Site
Hialeah, Florida
Research Site
Jacksonville, Florida
Research Site
Melbourne, Florida
Research Site
Orlando, Florida
Research Site
Indianapolis, Indiana
Research Site
Prairie Village, Kansas
Research Site
Wichita, Kansas
Research Site
New Orleans, Louisiana
Research Site
Shreveport, Louisiana
Research Site
Belmont, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Lincoln, Nebraska
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Dayton, Ohio
Research Site
Toledo, Ohio
Research Site
Salem, Oregon
Research Site
Allentown, Pennsylvania
Research Site
Bala-Cynwyd, Pennsylvania
Research Site
Bridgeville, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
San Antonio, Texas
Research Site
Murray, Utah
Research Site
Woodstock, Vermont
Research Site
Richmond, Virginia
Research Site
Seattle, Washington
Research Site
Penticton, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Gatineau, Quebec, Canada
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.